Evaluating the safety profile of semaglutide: an updated meta-analysis-Reference-Cited by-同舟云学术

Evaluating the safety profile of semaglutide: an updated meta-analysis

Published:2024-07-27 Issue:9 Volume:40 Page:1495-1514
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Rivera Frederick Berro¹^ORCID,Arias-Aguirre Eloise²,Aguirre Zedrick²^ORCID,Ybañez Mc John C.²,Rubia Janos Marc M.²,Galang Danica Janine²,Lumbang Grace Nooriza²,Ruyeras Jade Monica Marie J.²^ORCID,Magalong John Vincent³,Pine Polyn Luz⁴,Amigo John Andrew C.⁴,Ansay Marie Francesca M.⁵,Zelenkov Nenad⁵,Thomas Steve Samuel⁶,Vijayaraghavan Krishnaswami⁷

Affiliation:

1. Department of Medicine, Lincoln Medical Center, New York, NY, USA

2. Cebu Institute of Medicine, Cebu City, Philippines

3. College of Medicine, San Beda University, Manila, Philippines

4. Ateneo School of Medicine and Public Health, Manila, Philippines

5. Department of Family Medicine, University of Pittsburgh Medical Center (UPMC) McKeesport, McKeesport, PA, USA

6. Arizona State University, Tempe, AZ, USA

7. University of Arizona, Tucson, AZ, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2383731

Reference23 articles.

1. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

2. Klein HE. An ongoing crisis: SEMAGLUTIDE shortage raises dual concerns for obesity and diabetes treatment. AJMC; 2023 [cited 2024 Mar 3]. Available from: https://www.ajmc.com/view/an-ongoing-crisis-semaglutide-shortage-raises-dual-concerns-for-obesity-and-diabetes-treatment

3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

4. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

5. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes